L., and S. the wildtype, four mutants (K417N, Y453F, N501Y, and K417T/E484K/N501Y) got weaker affinity for the CC12.1 antibody, whereas two (S477N and S494P) had
Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy
mTORC1 inhibitor
mTORC1 inhibitor
L., and S. the wildtype, four mutants (K417N, Y453F, N501Y, and K417T/E484K/N501Y) got weaker affinity for the CC12.1 antibody, whereas two (S477N and S494P) had